Gamaleya Center begins clinical trials of drug against coronavirus

The Gamaleya Center has begun clinical trials of a drug against CORONAVIRUS based on monoclonal antibodies, its DIRECTOR Alexander Gintsburg said, TASS reports.

According to him, the scientists of the center should conduct the first two phases of testing in 3.5-4 months.

“But the fact that this drug is effective is already known from Western analogues,” Gunzburg said.

Monoclonal antibodies are produced by immune cells that originate from a single progenitor plasma cell.

Preparations based on them are used to treat migraine, melanoma, and breast cancer.